Andere talen WPD Pharmaceuticals Inc.

Aandelen

WBIO

CA92941F1053

Vertraagde tijd Canadian Securities Exchange Andere beurzen 15:49:31 28-06-2022			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,045 ^CAD	-.--%		-.--%	-.--%

05/02	WPD Pharmaceuticals Inc. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI
02/02	WPD Pharmaceuticals Inc. rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	05/02
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/02
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/01
WPD Pharmaceuticals : Sp. z o. o., received the second tranche of the funds	02/11
WPD Pharmaceuticals : Sp. z o. o., received the first tranche of the funds	08-09-23
WPD Pharmaceuticals : Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited	01-09-23
WPD Pharmaceuticals : Announces Closing of Convertible Debenture Private Placement	16-06-23
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding	15-06-23
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline	02-05-23
WPD Pharmaceuticals Inc. Announces Directorate Appointments	02-05-23
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding	01-05-23
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy	18-01-23
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)	19-12-22
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin	05-12-22
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022	25-11-22
WPD Pharmaceuticals : Provides a Corporate Update	18-11-22
WPD Pharmaceuticals Inc. announced that it expects to receive PLN 1.7 million in funding	14-09-22
IIROC Trading Halt - WBIO	11-07-22
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16-05-22
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16-05-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen WPD Pharmaceuticals Inc.

Aandelen

WBIO

CA92941F1053

Andere talen

Filters